Physician profile
Michael V Koss
NPI 1053365742
$1,058.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $194 · 2021: $319 · 2022: $63.88 · 2023: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $211.53 | 2019-2023 | Stelara, Simponi Aria, Remicade |
| Abbvie INC. | $162.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.24 | 2020-2023 | Gattex |
| Gilead Sciences, INC. | $109.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.34 | 2020-2022 | |
| Beigene USA, INC. | $96.67 | 2021 | |
| Csl Behring | $67.39 | 2019-2023 | Kcentra |
| Merck Sharp & Dohme LLC | $31.23 | 2019-2021 | |
| Qol Medical, LLC | $24.24 | 2019 | |
| Ferring Pharmaceuticals INC. | $20.66 | 2023 | Cimzia |
| Intercept Pharmaceuticals, INC. | $18.72 | 2023 | Ocaliva |
| Redhill Biopharma INC. | $17.36 | 2020 | |
| Shionogi INC | $17.25 | 2019 | |
| Pfizer INC. | $15.75 | 2021 | |
| Olympus America INC. | $14.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $13.08 | 2021 | |
| W. L. Gore & Associates, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Koss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.